Diabetes product integration
This article was originally published in The Gray Sheet
Executive Summary
Roche's goal of creating an artificial pancreas "sometime between 2008 and 2010" trumps short-term objective of being first to market with a continuous blood glucose measuring device, though such a monitor will begin clinical testing this year, von Prondzynski suggests Feb. 4. "Will we beat the competitors? Probably not. I don't think first to market is the most important thing here. I think what matters is quality," he offers. Roche forecasts successful FDA re-inspection of Disetronic unit's Burgdorf, Switzerland facility for late Q2, enabling firm to launch Minitron next-gen insulin pump in the U.S. by Q4. Roche will "take advantage of this year" as competitors Abbott and TheraSense will be pre-occupied with aligning their manufacturing capacity, von Prondzynski tells "The Gray Sheet"...